Stronger evidence: ForVerdict
The clinical evidence strongly supports the prioritization of Cognitive Behavioral Therapy (CBT) as a first-line treatment for mild-to-moderate depression over antidepressant medication. While both modalities show comparable efficacy in acute symptom reduction, CBT consistently outperforms medication in longitudinal durability and relapse prevention. The 2005 Hollon study demonstrated that CBT provides lasting skills that protect patients even after active therapy concludes, whereas medication-only patients often face high relapse rates once the drug is discontinued. Furthermore, for mild-to-moderate cases, the benefit-to-risk ratio leans heavily toward CBT, as it avoids the physiological side effects associated with SSRIs, such as weight gain, sexual dysfunction, and withdrawal symptoms. Major health organizations, including NICE, have shifted their guidelines to reflect this preference, recommending psychological interventions first. Although antidepressants are more easily accessible in many healthcare systems and provide faster relief for some, the long-term clinical and economic benefits of equipping patients with cognitive tools justify mandating CBT as the prerequisite first-line coverage before pharmacological escalation.
Ranked by citation count.
The debate
David: When we look at the data for mild-to-moderate depression, there is no reason we should be starting with a pill. The Hollon study from 2005 is clear: CBT doesn’t just treat the symptoms; it "teaches" the patient how to stay well. Patients who finish a course of CBT have a significantly lower relapse rate than those who just take an SSRI and then stop. We are talking about long-term mental resilience versus temporary chemical suppression.
Mark: I don’t disagree that CBT is effective, David, but we have to look at the reality of the Lancet 2018 meta-analysis. It confirmed that antidepressants work reliably across the board. For many patients, the barrier to CBT is time, cost, and availability. It can take months to see a therapist, while a primary care doctor can prescribe medication in fifteen minutes. If we force people to wait for CBT as a "first-line" requirement, we are effectively leaving them untreated while their condition potentially worsens into severe depression.
David: But that is a systemic failure, not a clinical one. If insurance covered CBT as the mandatory first-line, we would see an increase in providers and digital therapy options. The BMJ 2015 review showed no significant difference in efficacy between the two, so why would we choose the option that comes with side effects? SSRIs can cause sexual dysfunction, weight gain, and insomnia. Why subject a patient with mild depression to those risks when they could achieve the same results through cognitive restructuring?
Mark: Because "achieving results" is harder than it sounds in therapy. CBT requires significant cognitive effort and commitment. Some patients simply don’t have the bandwidth for it during a depressive episode. Medication can provide the "floor" they need to even begin engaging with their life again. The Cipriani study showed that medication is highly acceptable and effective. Forcing a specific sequence—CBT then meds—ignores patient preference, which we know from the Weitz meta-analysis is a huge predictor of outcome.
David: Patient preference is important, but evidence-based durability is more important. The goal isn’t just to feel better this month; it’s to prevent a recurrence in three years. CBT is essentially a "vaccine" for future episodes. Antidepressants are more like a crutch—useful, but the moment you take it away, the underlying vulnerability remains. For mild cases, we shouldn’t be reaching for a chemical solution first.
Mark: I still think the "medication-first" or "equal-choice" model is safer. If a patient is struggling to get out of bed, tell them to wait six weeks for a therapy appointment is risky. Let’s provide the relief first, then integrate therapy. The evidence suggests they are equal in the short term, so accessibility should dictate the first step.
Frequently asked questions
Is CBT as effective as antidepressants for depression?
Several meta-analyses, including a 2015 BMJ review and a 2013 analysis of over 100 trials, found no meaningful difference in effectiveness between CBT and antidepressants for treating depression.
Does CBT prevent depression from coming back better than medication?
A 2005 study found that people treated with CBT were significantly less likely to relapse after treatment stopped than those who took medication alone. The skills learned in therapy appear to offer protection after sessions end, while relapse is common when medication is discontinued.
Do antidepressants work for mild depression?
A 2024 network meta-analysis found no evidence that antidepressants are effective in mild-to-moderate depression, and a 2025 review suggested they may be inappropriate for subclinical depression. A 2018 analysis did find antidepressants effective against placebo for acute treatment of major depressive disorder.
Why might someone choose antidepressants before therapy?
Antidepressants are often more readily available than therapy in many healthcare systems and can provide faster relief for some people. Therapy avoids medication side effects such as weight gain, sexual dysfunction and withdrawal symptoms.